In the pursuit of the ultimate way to combat RSV and hMPV, the combination VLP vaccine, IVX-A12, is a blend of two vaccines previously being developed separately the IVX-RSV and the IVX-hMPV. The combination of these two has shown promising results in interim Phase 2, thereby justifying the move towards a combined vaccine.
Phase 2 trials, which involve hundreds of participants, are primarily focused on ascertaining the efficiency and possible side effects of a new treatment or vaccine. The encouraging results obtained from this phase are vital for progressing to Phase 3, which will involve thousands of participants and is the ultimate testing ground for the safety and efficacy of the new treatmen...

ICVX's Stock Performance relative to it's Customers

ICVX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Icosavax Inc	765.97	0.58	-96.71	31
SUBTOTAL	0.00	0.00	0.00	-

Sources: Icosavax Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Icosavax Inc’s corporate clients.
For your research, we’ve provided 9 tables on Icosavax Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.